Frontlight ResearchEarly access
Pompe disease trials in United States
5 of 13 trials · From ClinicalTrials.gov, checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 1/2Taking peopleA Study to Evaluate Safety, Tolerability, and Efficacy of AB-1009 Gene Therapy (GAA Gene) in Adult Participants With Late-Onset Pompe Disease (PROGRESS-GT LOPD)
- Where
- Dallas, Durham, Irvine, New York, Palo Alto, Philadelphia, Phoenix, Pittsburgh, Richmond
- Age
- 18 years to 65 years
- People
- 12
- Run by
- AskBio Inc
See details and how to joinNCT07282847 - Phase 1Taking peopleA Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL952 in Adult Participants With Late-Onset Pompe Disease
- Where
- Durham, Fairfax, Irvine, St Louis
- Age
- 18 years to 75 years
- People
- 32 worldwide
- Run by
- Denali Therapeutics Inc.
See details and how to joinNCT07354724 · EU 2025-524082-25-00 - Phase 2Taking peopleStudy of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD)
- Where
- Atlanta, Cincinnati, Durham, Fairfax, Gainesville, Irvine, Philadelphia, Pittsburgh, St Louis
- Age
- 18 years and over
- People
- 45 worldwide
- Run by
- Shionogi
See details and how to joinNCT07123155 - Phase 1Taking peoplePEARL (PrEnAtal Enzyme Replacement Therapy for Lysosomal Storage Disorders)
- Where
- San Francisco
- Age
- 18 years to 50 years
- People
- 10
- Run by
- University of California, San Francisco
See details and how to joinNCT04532047 - Phase 3Taking peopleA Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18
- Where
- Atlanta, Cincinnati, Durham, Gainesville, Pittsburgh, Salt Lake City
- Age
- Up to 17 years
- People
- 36 worldwide
- Run by
- Amicus Therapeutics
See details and how to joinNCT04808505 · EU 2022-501095-25-01